Continuous glycemic monitoring in managing diabetes in adult patients with wolfram syndrome.
Continuous glucose monitoring system
GlyCulator
Glycemic variability
Type 1 diabetes
Wolfram syndrome
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
03 Aug 2024
03 Aug 2024
Historique:
received:
15
03
2024
accepted:
26
07
2024
medline:
4
8
2024
pubmed:
4
8
2024
entrez:
3
8
2024
Statut:
aheadofprint
Résumé
In this study we evaluated the use of Continuous Glucose Monitoring system in adults with insulin-dependent diabetes in the course of Wolfram syndrome (WFS) in comparison to patients with type 1 diabetes (T1D). Individuals with WFS (N = 10) used continuous glucose monitoring for 14 days and were compared with 30 patients with T1D matched using propensity score for age and diabetes duration. Glycemic variability was calculated with Glyculator 3.0. We revealed significant differences in glycemic indices between adults with Wolfram syndrome-related diabetes and matched comparison group. Patients with Wolfram syndrome presented lower mean glucose in 24-h and nighttime records [24h: 141.1 ± 30.4mg/dl (N = 10) vs 164.9 ± 31.3mg/dl (N = 30), p = 0.0427; nighttime: 136.7 ± 39.6mg/dl vs 166.2 ± 32.1mg/dl (N = 30), p = 0.0442]. Moreover, they showed lower standard deviation of sensor glucose over all periods [24h: 50.3 ± 9.2mg/dl (N = 10) vs 67.7 ± 18.7 mg/dl (N = 30), p = 0.0075; daytime: 50.8 ± 8.7mg/dl (N = 10) vs 67.4 ± 18.0mg/dl (N = 30), p = 0.0082; nighttime: 45.1 ± 14.9mg/dl (N = 10) vs 65.8 ± 23.2mg/dl (n = 30), p = 0.0119] and coefficient of variation at night [33.3 ± 5.8% (N = 10) vs 40.5 ± 8.8% (N = 30), p = 0.0210]. Additionally, WFS patients displayed lower time in high-range hyperglycemia (> 250mg/dl) across all parts of day [24h: 4.6 ± 3.8% (N = 10) vs 13.4 ± 10.5% (N = 30), p = 0.0004; daytime: 4.7 ± 3.9% (N = 10) vs 13.8 ± 11.2% (N = 30), p = 0.0005; nighttime: 4.2 ± 5.5% (N = 10) vs 12.1 ± 10.3% (N = 30), p = 0.0272]. Adult patients with Wolfram syndrome show lower mean blood glucose, less extreme hyperglycemia, and lower glycemic variability in comparison to patients with type 1 diabetes.
Identifiants
pubmed: 39096330
doi: 10.1007/s00592-024-02350-w
pii: 10.1007/s00592-024-02350-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating Improved Glycemic outcomes. Diabetes Technol Ther 19(S3):S25–S37. https://doi.org/10.1089/dia.2017.0035
doi: 10.1089/dia.2017.0035
pubmed: 28585879
Zmyslowska A, Fendler W, Szadkowska A, Borowiec M, Mysliwiec M, Baranowska-Jazwiecka A, Buraczewska M, Fulmanska-Anders M, Mianowska B, Pietrzak I, Rzeznik D, Mlynarski W (2015) Glycemic variability in patients with Wolfram syndrome is lower than in type 1 diabetes. Acta Diabetol 52(6):1057–1062. https://doi.org/10.1007/s00592-015-0757-5
doi: 10.1007/s00592-015-0757-5
pubmed: 25916214
pmcid: 4628085
Iafusco D, Zanfardino A, Piscopo A, Curto S, Troncone A, Chianese A, Rollato AS, Testa V, Iafusco F, Maione G, Pennarella A, Boccabella L, Ozen G, Palma PL, Mazzaccara C, Tinto N, Giudice MD, E (2022) Metabolic treatment of Wolfram Syndrome. Int J Environ Res Public Health 19(5):2755. https://doi.org/10.3390/ijerph19052755
doi: 10.3390/ijerph19052755
pubmed: 35270448
pmcid: 8910219
Zmyslowska A, Borowiec M, Antosik K, Szalecki M, Stefanski A, Iwaniszewska B, Jedrzejczyk M, Pietrzak I, Mlynarski W (2011) Wolfram syndrome in the Polish population: novel mutations and genotype-phenotype correlation. Clin Endocrinol 75(5):636–641. https://doi.org/10.1111/j.1365-2265.2011.04102.x
doi: 10.1111/j.1365-2265.2011.04102.x
Chrzanowski J, Grabia S, Michalak A, Wielgus A, Wykrota J, Mianowska B, Szadkowska A, Fendler W, Data Sharing (2023) Diabetes Care 46(1):e3–e5. https://doi.org/10.2337/dc22-0534 . GlyCulator 3.0: A Fast, Easy-to-Use Analytical Tool for CGM Data Analysis, Aggregation, Center Benchmarking
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Phillip M (2019) Clinical targets for continuous glucose Monitoring Data Interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
Cano A, Molines L, Valéro R, Simonin G, Paquis-Flucklinger V, Vialettes B, French Group of Wolfram Syndrome (2007) Microvascular diabetes complications in Wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness [DIDMOAD]): an age- and duration-matched comparison with common type 1 diabetes. Diabetes Care 30(9):2327–2330. https://doi.org/10.2337/dc07-0380
doi: 10.2337/dc07-0380
pubmed: 17536072